Stock Research for CORT


Featured Broker: Ally Invest

Get the due diligence for another stock.


CORT Stock Chart & Research Data

The CORT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CORT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CORT Due diligence Resources & Stock Charts

The CORT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CORT Detailed Price Forecast - CNN Money CNN View CORT Detailed Summary - Google Finance
Yahoo View CORT Detailed Summary - Yahoo! Finance Zacks View CORT Stock Research & Analysis -

Stock Analysis

TradeIdeas View CORT Trends & Analysis - Trade-Ideas Barrons View CORT Major Holders - Barrons
NASDAQ View CORT Call Transcripts - NASDAQ Seeking View CORT Breaking News & Analysis - Seeking Alpha
Spotlight View CORT Annual Report - OTC Report View CORT OTC Short Report -
TradeKing View CORT Fundamentals - TradeKing Charts View CORT SEC Filings - Bar Chart
WSJ View Historical Prices for CORT - The WSJ Morningstar View Performance/Total Return for CORT - Morningstar
MarketWatch View the Analyst Estimates for CORT - MarketWatch CNBC View the Earnings History for CORT - CNBC
StockMarketWatch View the CORT Earnings - StockMarketWatch MacroAxis View CORT Buy or Sell Recommendations - MacroAxis
Bullish View the CORT Bullish Patterns - American Bulls Short Pains View CORT Short Pain Metrics -

Social Media Mentions

StockTwits View CORT Stock Mentions - StockTwits PennyStocks View CORT Stock Mentions - PennyStockTweets
Twitter View CORT Stock Mentions - Twitter Invest Hub View CORT Investment Forum News - Investor Hub
Yahoo View CORT Stock Mentions - Yahoo! Message Board Seeking Alpha View CORT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CORT - Insider Cow View Insider Transactions for CORT - Insider Cow
CNBC View CORT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CORT - OTC Markets
Yahoo View Insider Transactions for CORT - Yahoo! Finance NASDAQ View Institutional Holdings for CORT - NASDAQ

Stock Charts

FinViz View CORT Stock Insight & Charts - StockCharts View CORT Investment Charts -
BarChart View CORT Stock Overview & Charts - BarChart Trading View View CORT User Generated Charts - Trading View

Latest Financial News for CORT

Biotech Companies in the News
Posted on Thursday December 13, 2018

HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season. We are highlighting: Endonovo ...

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
Posted on Thursday December 13, 2018

Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome).  The patent will expire in 2037. “This patent covers an important finding of our research – that with proper dose modulation, Korlym can safely be administered in combination with medications that are strong CYP3A inhibitors,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.

IBD 50 Stocks To Watch: Corcept Expected To Pick Up Growth In 2019
Posted on Wednesday December 12, 2018

Biotech Corcept develops drugs to treat cortisol activity, such as Cushing's disease. The chief drug is Korlym, also known as mifepristone.

Today's Research Reports on Trending Tickers: MYOS RENS Technology and Corcept Therapeutics
Posted on Wednesday December 12, 2018

NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Shares of MYOS RENS and Corcept Therapeutics were two biotech stocks seeing huge gains in Tuesday’s trading session. MYOS RENS shares soared after news of its product being launched with The Vitamin Shoppe. The fact that a generic version of Corcept Therapeutics’ Korlym drug may not happen for a while had traders cheering and sending the stock higher.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.